Cover Image

Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M

New 1H-pyrazolo[3,4-d]pyrimidine derivatives were designed and synthesised to act as epidermal growth factor receptor inhibitors (EGFRIs). The synthesised derivatives were assessed for their in vitro anti-proliferative activities against A549 and HCT-116 cancer cells. Compounds 8, 10, 12a, and 12b s...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ahmed A. Gaber (Author), Mohamed Sobhy (Author), Abdallah Turky (Author), Hanan Gaber Abdulwahab (Author), Ahmed A. Al-Karmalawy (Author), Mostafa. A. Elhendawy (Author), Mohamed. M. Radwan (Author), Eslam B. Elkaeed (Author), Ibrahim M. Ibrahim (Author), Heba S. A. Elzahabi (Author), Ibrahim H. Eissa (Author)
Format:	Book
Published:	Taylor & Francis Group, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers
by: Heba S. A. Elzahabi, et al.
Published: (2022)

Biological evaluation, docking studies, and in silico ADME prediction of some pyrimidine and pyridine derivatives as potential EGFRWT and EGFRT790M inhibitors
by: Tarfah Al-Warhi, et al.
Published: (2023)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFRWT, EGFRT790M, and EGFRL858R)
by: Mahmoud G. Abo Al-Hamd, et al.
Published: (2023)

Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M
by: Moustafa O. Aboelez, et al.
Published: (2022)

Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity
by: Asmaa A. Mandour, et al.
Published: (2022)

Pyrazolo[3,4-d]pyrimidine based scaffold derivatives targeting kinases as anticancer agents
by: Nasser S.M. Ismail, et al.
Published: (2016)

Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFRWT/EGFRT790M inhibitors
by: Lamya H. Al-Wahaibi, et al.
Published: (2023)

Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-d]pyrimidine derivatives as new EGFR inhibitors
by: Eman A. Sobh, et al.
Published: (2023)

Medicinal attributes of pyrazolo[1,5-a]pyrimidine based scaffold derivatives targeting kinases as anticancer agents
by: Nasser S.M. Ismail, et al.
Published: (2016)

Discovery of new quinolines as potent colchicine binding site inhibitors: design, synthesis, docking studies, and anti-proliferative evaluation
by: Mohamed Hagras, et al.
Published: (2021)

Design, synthesis and antitumor evaluation of novel pyrazolo[3,4-d]pyrimidines incorporating different amino acid conjugates as potential DHFR inhibitors
by: Ibrahim M. Salem, et al.
Published: (2023)

Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies
by: Mohamed M. Khalifa, et al.
Published: (2022)

The Role of Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitors in The Attenuation of CCl<sub>4</sub>-Induced Liver Fibrosis in Rats
by: Diana K. Ghobrial, et al.
Published: (2023)

Design of more potent quinazoline derivatives as EGFRWT inhibitors for the treatment of NSCLC: a computational approach
by: Muhammad Tukur Ibrahim, et al.
Published: (2021)

Molecular Docking and Dynamics Simulations Reveal the Potential of Anti-HCV Drugs to Inhibit COVID-19 Main Protease
by: Ahmed Ali Al-Karmalawy, et al.
Published: (2021)

Design and synthesis of novel pyrazolo[4,3-d]pyrimidines as potential therapeutic agents for acute lung injury
by: Bao Shi Wang, et al.
Published: (2019)

Novel Glu-based pyrazolo[3,4-d]pyrimidine analogues: design, synthesis and biological evaluation as DHFR and TS dual inhibitors
by: Mater Mahnashi, et al.
Published: (2023)

Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFRL858R/T790M inhibitors
by: Jianfang Fu, et al.
Published: (2023)

A PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND REDUCES CELL VIABILITY AND INDUCES APOPTOSIS IN DIFFERENT HEMATOLOGICAL MALIGNANCIES
by: Ilaria Laurenzana, et al.
Published: (2016)

Antibiofilm and Anti-Quorum-Sensing Activities of Novel Pyrazole and Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Carbonic Anhydrase I and II Inhibitors: Design, Synthesis, Radiosterilization, and Molecular Docking Studies
by: Ahmed Ragab, et al.
Published: (2023)

Halloysite Nanotube-Based Delivery of Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives for Prostate and Bladder Cancer Treatment
by: Marina Massaro, et al.
Published: (2024)

Synthesis of some novel pyrazolo[3,4-d] pyrimidin-4(5H)-one derivatives as potential antimicrobial agent
by: Dipen K Sureja, et al.
Published: (2016)

Identification and Biological Characterization of the Pyrazolo[3,4-<i>d</i>]pyrimidine Derivative SI388 Active as Src Inhibitor
by: Claudia Contadini, et al.
Published: (2023)

Design, ADMET, PASS Prediction and Molecular Docking Studies of Novel pyrazolo[3,4-d]pyrimidines for Prospective of Anti-Cancer Agents
by: Sathish Mittapalli, et al.
Published: (2023)

Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
by: Ibrahim H. Eissa, et al.
Published: (2023)

Evaluation of primary repair of common bile duct in common bile duct stones
by: Mohamed A Abdel-Raheem, et al.
Published: (2016)

Role of pH in Regulating Cancer Pyrimidine Synthesis
by: Saad Saeed Alqahtani, et al.
Published: (2022)

Design, synthesis, molecular docking and anticonvulsant evaluation of novel 6-iodo-2-phenyl-3-substituted-quinazolin-4(3H)-ones
by: Mohamed-Kamal Ibrahim, et al.
Published: (2015)

DMH1 (4-[6-(4-isopropoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) inhibits chemotherapeutic drug-induced autophagy
by: Yue Sheng, et al.
Published: (2015)

Design, synthesis, docking, and antimicrobial evaluation of some novel pyrazolo[1,5-a]pyrimidines and their corresponding cycloalkane ring-fused derivatives as purine analogs
by: Abdallah AEM, et al.
Published: (2018)

Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold
by: Heba S. A. Elzahabi, et al.
Published: (2018)

Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies
by: Reda G. Yousef, et al.
Published: (2022)

New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies
by: Hazem Elkady, et al.
Published: (2022)

Synthesis and Structure-Activity Relationships for the Anti-Mycobacterial Activity of 3-Phenyl-<i>N</i>-(Pyridin-2-ylmethyl)Pyrazolo[1,5-<i>a</i>]Pyrimidin-7-Amines
by: Hamish S. Sutherland, et al.
Published: (2022)

Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-<i>d</i>]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme
by: Federica Poggialini, et al.
Published: (2023)

Targeting p21-activated kinase 4 (PAK4) with pyrazolo[3,4-d]pyrimidine derivative SPA7012 attenuates hepatic ischaemia-reperfusion injury in mice
by: Yuancheng Mao, et al.
Published: (2022)

Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies
by: Mohammed S. Taghour, et al.
Published: (2022)

1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies
by: Mohamed Hagras, et al.
Published: (2022)

New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies
by: Eslam B. Elkaeed, et al.
Published: (2022)

Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors
by: Amany Belal, et al.
Published: (2022)